Pfizer Inc. (NYSE:PFE) Stake Raised by Ledyard National Bank

Ledyard National Bank grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 377,732 shares of the biopharmaceutical company’s stock after purchasing an additional 13,266 shares during the period. Pfizer comprises approximately 1.1% of Ledyard National Bank’s portfolio, making the stock its 27th biggest holding. Ledyard National Bank’s holdings in Pfizer were worth $10,875,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Briaud Financial Planning Inc bought a new stake in Pfizer during the third quarter worth approximately $30,000. GoalVest Advisory LLC boosted its stake in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. bought a new stake in shares of Pfizer during the 3rd quarter worth $34,000. VisionPoint Advisory Group LLC raised its position in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer during the fourth quarter worth $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 1.0 %

NYSE:PFE traded up $0.25 during mid-day trading on Monday, reaching $25.65. The stock had a trading volume of 41,630,566 shares, compared to its average volume of 41,999,020. The stock has a market cap of $145.24 billion, a P/E ratio of 71.25, a PEG ratio of 1.14 and a beta of 0.61. The business’s 50 day moving average is $26.92 and its 200 day moving average is $28.31. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $40.37.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the prior year, the business posted $1.14 EPS. Pfizer’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, sell-side analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.55%. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.